Our pipeline
We have an exciting and balanced pipeline underpinned by great science.
Home / Our therapy areas / Our pipeline
Latest quarterly updates
Our pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.
180
projects in our pipeline
116
new molecular entities (NME) or major lifecycle management (LCM) projects in Phase II or Phase III
20
NME's in our late-stage pipeline
2
NME's under review
Includes NME and major life-cycle management projects up to launch in applicable major markets.
Oncology (as of 30 October 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Cardiovascular, Renal and Metabolism (as of 30 October 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Respiratory & Immunology (as of 30 October 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 30 October 2026)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Infectious Disease (as of 30 October 2026)
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects